As of June 9, 2020,
a 美国 专利 (10/675,294) for a 制药 composition for the treatment of 角膜损伤 containing 8-oxo-2'-deoxyguanosine or a 制药ly acceptable salt thereof as an active ingredient
has been registered, and we are pleased to announce this achievement. Based on this 专利, RudaCure is simultaneously pursuing 美国 临床试验 and preparing for its 美国 market entry.